(1R,2S)-VU0155041 is primarily used in research settings to study its effects on specific biochemical pathways. It acts as a selective positive allosteric modulator of the metabotropic glutamate receptor subtype 4 (mGluR4), which is involved in modulating neurotransmitter release and synaptic plasticity. This compound is particularly valuable in neuroscience research for investigating the role of mGluR4 in neurological disorders such as Parkinson's disease, anxiety, and depression. By enhancing the receptor's activity, it helps researchers understand the potential therapeutic benefits of targeting mGluR4 in these conditions. Additionally, it is used in preclinical studies to explore its efficacy in reducing motor symptoms and neuroprotective effects in Parkinson's disease models. Its application extends to drug discovery efforts aimed at developing novel treatments for neurodegenerative and psychiatric disorders.